Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Naltrexone for Chronic Pain in Arthritis
NCT04115020Phase 2Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2020
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PsA) and 1 more comparing Naltrexone first with Placebo first (2 arms). Primary endpoint: Brief Pain Inventory - Pain Interference at 16 weeks. Planned start Jan 2020; status: withdrawn.
02
Drugs
naltrexone
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)psoriatic arthritis (PsA)spondyloarthritis (SpA)
Beyond the preview
Go deeper on NCT04115020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115020.